
BMIæ£åžžãªã®ã«ãå èèèªã ããã ã£ãïœTOFIãšãããªã¹ã¯
äœéãå€ãã£ãŠããªããã倧äžå€«ã ããæã£ãŠãã人ããäžçªå±ãªãã
ããçµå¶è ã«ããèšãããããšãããã
ã俺ã¯å€ªã£ãŠãªãããå¥åº·ã ãã
BMIã¯22ãèŠãç®ããµã€ãäœåãã¹ãŒãã®çããªãããããèªåããã®å Žã§ã¯ãããã§ããããšè¿ãããã§ã人éããã¯ã§æ®ã£ãå èèèªCTãèŠãããå èãèèªã«ã³ã£ããå²ãŸããŠããã
èªåãããŒãœãã«ãã¯ã¿ãŒãšããŠèšºãŠããäžã§ãBMIãæ£åžžãªã®ã«å èèèªãã³ã£ãããšãã人ã¯äœäººããããå¥èšºã§ãç°åžžãªãããããã£ãŠãå®å¿ããŠãã人ãã¡ã ã
ä»åã¯ãBMIãæ£åžžã§ãå èèèªãå±éºã¬ãã«ã«ããŸã£ãŠãããTOFIããšåŒã°ããç¶æ ã«ã€ããŠæžããããåã®èèªèã»é ãè¥æºã»å¥èšºã¯Aå€å®ãªã®ã«äžæ§èèªãALTãããããäžãã£ãŠãã人ã«ã¯ããã®ãŸãŸäœ¿ããå 容ã«ããã€ããã ã
äœéèšã¯ãå èèèªãæ ããªã
å»åŠã®äžçã«ã¯ãTOFIãšããæŠå¿µããããå€ã¯çްãã®ã«ãäžã¯èèªã ãããããããç¶æ ãæãèšèã ã

èŠãç®ã¯ãµã€ããäœéãæ£åžžãBMIãåºæºå€å ãã§ãå èèèªãèèãªã©ãå€ããèŠããªãå Žæã«èèªãããŸã£ãŠãã人ãããã
ãã®æŠå¿µãè«æãšããŠæç¢ºã«ç€ºããã®ããã€ã³ããªã¢ã«ã»ã«ã¬ããžã»ãã³ãã³ã®ç ç©¶ããŒã ã ã477åãMRIã§èª¿ã¹ãBMIãèŠãç®ã ãã§ã¯å èèèªãèèå èèªãæŸããããªããšå ±åããŠãããTOFIã¯ã代è¬ãªã¹ã¯ã®é«ãã¿ã€ããšããŠææ¡ãããŠãã¹âŸã
äœéèšã®æ°åã¯æ£åžžãªã®ã«ã身äœã®äžã§ã¯ãã§ã«å±éºãªç¶æ ãé²ãã§ããã
èªåã蚺ãŠããç¯å²ã§ã¯ããã®ãã¿ãŒã³ã¯å°ãªããªããç¹ã«40代以éã®ç·æ§çµå¶è ãé£äºã¯å€é£ã¡ã€ã³ãéåã¯ãŒããã§ãé£ã¹ãéã¯å°ãªãããäœéã¯å€ãããªãããã®ãã¿ãŒã³ãäžçªå€ãã
äœéãBMIã®ãäžèº«ããçèãšèèªã«åããææšã«ãFFMIãããã30ç§ã§èšç®ã§ããŠãæžã£ãã®ãèèªãçèãã远ããããã®ææšã®è©±ã¯ãã¡ã³ããŒéå®èšäºã俺ãè¥æºã£ããïŒãå è€æµ©æ¬¡ããã«èãããŠèãããBMIã®ç²ç¹ïœFFMIã®ã¹ã¹ã¡ã§æžããã
å°é£ãªã®ã«ãå èèèªãå¢ããçç±
åé ã®çµå¶è ã®ç掻ã¯ããã ã£ããéåã¯ããªããé£äºã¯å€é£ãšé ãã¡ã€ã³ãã§ãé£ã¹ãéã¯å°ãªããã倪ããªãã
æ¬äººã¯ãå°é£ã ãã倧äžå€«ããšæã£ãŠãããå®éãäœéã¯ãã£ãšå€ãã£ãŠããªãã£ããæ°æã¡ã¯åãããé£ã¹ãéãå¢ããŠããªãã®ãªãã倪ãçç±ããªããæ®éã¯ããèããã
ã§ãåé¡ã¯ãéããããªããŠãäžèº«ãã ã
é£ã¹ãéãå€ããªããŠããç³è³ªã»è質ã»ã¢ã«ã³ãŒã«ã«å¯ã£ãé£ç掻ãšéåäžè¶³ãç¶ããšãèèªã®ããŸãå Žæãå€ããããšããããããã¯äœéã ãã§ã¯èŠããªãåé¡ã ããããå€ãã®äººãåéãããŠããã
éåãããŠããªããšãçèéãå¹Žã æžã£ãŠãããçèãæžããšãç³ãåãæ¢ããå ŽæãæžãããããžäŒé£ã»ç· ãã®çæ°Žåç©ã»å¯ãåã®é ã»çã飲ã¿ç©ãå ¥ãç¶ããã
äœéã¯å¢ããªããã§ãå åŽã§ã¯ãäœã£ããšãã«ã®ãŒã®è¡ãå Žãå°ããã€å€ãã£ãŠãããç®äžèèªã¯èŠãç®ã«åºããã ããã倪ã£ãããšæ°ã¥ããã
å èèèªã¯äœéèšã«ãé¡ã«ãæ ããªãã
ã ããå±ãªãã
ã¡ãªã¿ã«èªåã¯ãã¬ãŒãã³ã°ãé·ãã®ã§ãçèã§éããåŽã®äººéãªãã ãã©ãããã§ãäžææãæžéããµãã£ãŠå èèèªããããããšã«ãªã£ãããšããããçãã¬æŽãé·ããŠãæ²¹æããç¬éã«ããŸãã
å èèèªã¯ããã ã®èèªã§ã¯ãªã
TOFIã®ç¶æ ãæŸçœ®ãããšã©ããªããã
å èèèªã¯ããã ããã«ããã ããããªããå¢ãããããšãèèªãã®ãã®ãççãèµ·ããç©è³ªïŒã¢ãã£ããµã€ãã«ã€ã³ïŒãåºãå§ããããããå šèº«ã«åã£ãŠãå°ããã€æªããããã
ãã®çµæãã€ã³ã¹ãªã³ïŒè¡ç³ãäžãããã«ã¢ã³ïŒãå¹ãã«ãããªããç³å°¿ç ã®ãªã¹ã¯ãäžãããåæã«ããã®ççãã ãã ããšç¶ããŠãè¡ç®¡ã®å å£ã«ãã¡ãŒãžãäžããã
åè硬åã¯ããããããšããããéãã«é²ãã
2013幎ã®ã¡ã¿åæïŒå ç§åŠã®å°éèªAnnals of Internal MedicineïŒããããäœéãæ®éã§ãè¡æ¶²æ€æ»ãè¡å§ã®æ°åãæªã人ã¯ãåããããã®äœéã§æ€æ»å€ãããããªäººãšæ¯ã¹ãŠã æ»äº¡ãå¿è¡ç®¡ã€ãã³ãã®ãªã¹ã¯ãçŽ3.1åã ã£ã ²âŸã

ãã ãããã¯èгå¯ç ç©¶ã®ã¡ã¿åæã ãæ»äº¡ã ãã远ã£ãæ°åã§ã¯ãªããæ»äº¡ãšå¿è¡ç®¡ã€ãã³ããåãããŠæ°ããæ°åã ãã代è¬ç°åžžãçŽæ¥ã®åå ã§æ»äº¡ãå¿è¡ç®¡ã€ãã³ããå¢ããããšãŸã§ã¯èšããªããããã§ããBMIã ãã§å®å¿ããã®ã¯å±ãªããšããããšã¯ã¯ã£ããããŠããã
ã倪ã£ãŠãªãããç³å°¿ç ã«ã¯ãªããªãã
ãäœãæããªããã倧äžå€«ã
ã©ã¡ããå±éºãªæã蟌ã¿ã ã
çç¶ãåºãªãã¶ãããã®ãã¿ãŒã³ãäžçªæããäœèª¿ã«ç°å€ãæããªããŸãŸçªç¶åãããäºæ¥ã®ç¶ç¶ã«ãçŽçµãããèªåãããŒãœãã«ãã¯ã¿ãŒããã£ãŠããŠããã®ãªã¹ã¯ã ãã¯äœåºŠã§ãäŒããããã«ããŠããã
ç©ããŠããŠãèèªèã«ãªã
å
èèèªãå€ã人ã¯ãèèã«ãèèªãããŸãããããããããèèªèã ã
èèªèã¯æãããŸã倧ããããšãªãã§ããããããã®æ±ãã ã£ããèªåãåŠçã®ããããæç§æžã®èšèŒã¯è»œãã£ããšèšæ¶ããŠããã
ãšãããè¿å¹Žã®ç ç©¶ã§ããã®èªèã倧ããå€ãã£ããèèªèã®äžéšã¯èçïŒMASHâ·âŸïŒã«é²ã¿ãè硬å€ãèèããã«è³ãã
ãããŠãã®MASHã¯ã倪ã£ãŠãã人ã ãã®ç
æ°ã§ã¯ãªããBMIãæ£åžžã§ããèèã«èèªãããŸãã代è¬ç°åžžãéãªãã°èµ·ããããã
2020幎ã«äžçäžã®ç ç©¶ãéããè§£æã§ã¯ã倪ã£ãŠããªã人ã®èèªèããäžçå
šäœã§ç¡èŠã§ããªãå²åã«éããŠãããšå ±åããã³âŸã
é
ã飲ãŸãªããŠãèèªèã«ãªãã倪ã£ãŠããªããŠãèèªèã«ãªãã
ãã®äºå®ããŸã ç¥ããªã人ãå€ãã
ãããæ¥æ¬äººã®å Žåãããåã®èèªèã¯çãããªãã2021幎ã73ç ç©¶ã»çŽ26äžäººãçµ±åããæ¥æ¬ã®ã¡ã¿åæã§ã¯ãèèªèã®äººã®çŽ2å²ãBMI23æªæºã®ãããåãã ã£ãâŽâŸã
5人ã«1人ã
ããããŠããããèèªèãããªãã ãããã¯éçšããªãã
èèªèãã®ãã®ã®è©±ã¯ãç©ããŠãèèªèãæ²»ããªã人ã®å
±éç¹ã§æ°ããè«æãšäžç·ã«æãäžãããäœéãèœãšããŠãèèªèãæ®ã人ãããã®ã¯ãªãããåããã
å¥èšºç¥šã§ããŸãèŠè¿ããŠã»ããæ°å
TOFIã®ãªã¹ã¯ãäžããããã«æåã«ããã®ã¯ãå¥èšºç¥šãèŠè¿ãããšã ã
BMIãæ£åžžã§ããæ¬¡ã®æ°åãããããæªããªã£ãŠããäººã¯æ³šæããŠã»ããã
äžæ§èèª
HDLã³ã¬ã¹ãããŒã«
HbA1c
ALT
γ-GTP
è¡å§
è ¹å²
ã²ãšã€ã ãã§èšºæããã®ã§ã¯ãªããŠãç·åçã«ã¿ãå¿ èŠããããããããããã£ãŠæªãåŽã«ãããŠãããªãããäœéã¯å€ãã£ãŠããªããã©èº«äœã®äžèº«ã¯å€ãã£ãŠãããããããªãããšèããã»ããããã
倿¥ã§æãã®ã¯ãåçºã®ç°åžžå€ããããæ£åžžç¯å²ã®äžã§ããããæªããªã£ãŠãããã¿ãŒã³ã ãå»å¹Žããäžæ§èèªãäžãã£ããHDLãäžãã£ããALTãäžãã£ããHbA1cãå°ãäžãã£ããè ¹å²ãå¢ãããè¡å§ãäžãã£ãã
å šéšAå€å®ã§ãã䞊ã¹ããšæ¯è²ãå€ããã
å¥èšºç¥šã®æ°åãæšªã«äžŠã¹ãŠèªããšãäœãèŠããŠããããTG/HDLæ¯ã»ALTã®å幎差ã»eGFRã®äžããæ¹ãŸã§ãå¥èšºãªãŒã«Aã§ãçµããããªãçç±ã§è©³ããæžããã
å èèèªã®éã¯ãã©ããã£ãŠæž¬ãã®ã
äœéèšã®æ°åã ãã§ã¯ãå èèèªã®éã¯ããããªãã
ããã§åœ¹ã«ç«ã€ã®ããå¥åº·èšºæã®è ¹éšãšã³ãŒãšæ¡è¡ã ããšã³ãŒã§èèªèã®æç¡ããããããã ã軜床ã ãšèŠéãããšããããäžæ§èèªã»HbA1cã»ALTãªã©ã®æ¡è¡ããŒã¿ãšçµã¿åãããã°ãå èèèªãããŸã£ãŠããå¯èœæ§ãæŸããã
ãã ããšã³ãŒã¯ãèèªèããããã©ãããã¯ããã£ãŠããå èèèªã®éãæ£ç¢ºã«æž¬ãæ€æ»ã§ã¯ãªããæ¡è¡ããALTãæ£åžžã§ãèèªèãé ããŠããã±ãŒã¹ã¯ããã
ã ããèªåãçµå¶è ã«ããããŠããã®ã¯ãå¿ èŠãªäººã«ã¯ããäžæ©èžã¿èŸŒãã§ã人éããã¯ã§è ¹éšCTãæ®ã£ãŠãããããšã ã
èã®é«ãã§1æã¹ã©ã€ã¹ãæ®ãã ãã§ãå èèèªé¢ç©ïŒVFAïŒãæ°å€ã§ããããæ¥æ¬ã§ã¯100cm²以äžãå èèèªåè¥æºã®ç®å®ãšããŠäœ¿ãããŠããâžâŸã
ãã¡ããCTã«ã¯è¢«ã°ããããã®ã§ãå šå¡ãæ¯å¹Žããæ€æ»ã§ã¯ãªããå¥èšºç¥šã»è ¹å²ã»çæŽ»èæ¯ã»å®¶ææŽã確èªããŠãå¿ èŠãªäººãéžã¶æ€æ»ã ãšæã£ãŠããã
VFAã»ç©ºè ¹æã€ã³ã¹ãªã³ã»ApoBã»é«æåºŠCRPã»é žåèãšã³ãŒãããããé ç®ã¯ãæšæºã®å¥èšºã«ã¯å ¥ã£ãŠããªãããšãå€ãã 調ã¹ãŠããªããã®ã¯ãèŠã€ãããªãã
ãã®äžã®ApoBã¯ãLDLãæ£åžžã§ãåè硬åã®ãªã¹ã¯ãæŸããææšã ããªãLDLæ£åžžã§ã枬ãã¹ããã¯ããã®èšäºã§æžããã
å¥èšºã®ãç°åžžãªããã§ã¯æŸããªãæ€æ»é ç®ãã©ããŸã§è¿œå ãã¹ããã¯ãã¡ã³ããŒéå®èšäºãªãŒã«Aã®æ»è§ãè¡ç®¡ãæ¬åœã«å®ãããã®æ€æ»ãšç掻ãããã³ã«å®å šçã§ããªã现ããæžããã
ãŸãã¯ãèªåã®å èèèªãã©ãããããããããããæ°åã§çãããããããã¹ã¿ãŒãã©ã€ã³ã ã
é£äºã®éãæžããã°ã解決ããã®ã
ããããé£äºã®éãæžããã°ããã®ããTOFIã®åå ã¯ãåçŽãªé£ã¹ããã ãã§ã¯ãªããé£äºã®äžèº«ã»éåäžè¶³ã»çèéã®äœäžãéãªã£ãŠèµ·ããã
å€é£äžå¿ã®çµå¶è ã¯ãé£ã¹ãéã¯å°ãªããŠããç³è³ªã»è質ã»ã¢ã«ã³ãŒã«ã«å¯ãããããæŒã¯äžŒãã®ãå€ã¯é ãšåºèº«å°ã ãç· ãã«éººãæã¯ã³ãŒããŒã ããããã ãšäœéã¯å¢ãã«ããã®ã«ãå èèèªãšèèªèã¯ããŸããããã
倿¥ã§é£äºã®è©±ããããšããèªåã¯æåã«ã3ã€ã ãå€ããŠãã ããããšäŒãããå šéšã¯ç¡çã ãããå¹ããšãããã3ã€ã ã
â ã¿ã³ãã¯è³ªãå¢ãã
å€é£äžå¿ã®äººã¯ãæã£ãŠããããã¿ã³ãã¯è³ªãè¶³ããŠããªããè
æ©èœã«åé¡ããªã人ãªãã1æ¥ãããäœéÃ1.2gãç®å®ã«ãªããäœé70kgãªã84gãããããªãããã¯éåç¿æ
£ããªã人ã®ã©ã€ã³ãªã®ã§ãçãã¬ãå§ãã人ã¯ãããããããã«å¢ããïŒäœéÃ1.6gïŒã
ã¿ã³ãã¯è³ªãè¶³ããªããšãäœã¯äžè¶³åãæ±ããŠé£ã¹ããããšãã説ãããããããã€ã³ã»ã¬ãã¬ããžä»®èª¬ãšåŒã°ãããã®ã§ãããããæ¢ãŸããªããªã話ãšäžç·ã«ãã®èšäºã§æžããã
â¡ã¢ã«ã³ãŒã«ã®é »åºŠãäžãã
ã¢ã«ã³ãŒã«ã¯èèã§ã®èèªåæãä¿ãããéã¯å°ãªããã倧äžå€«ãã§ã¯ãªããç·éãšé »åºŠã§èãããæ¯æ¥é£²ãã§ãããªãããŸã飲ãŸãªãæ¥ãé±ã«æ°æ¥ã€ãããšããããã§ããã
â¢çã飲ã¿ç©ãšç²Ÿè£œç³è³ªãæžãã
çœç±³ã»ãã³ã»éººé¡ã»çã飲æãå®å
šã«ãããå¿
èŠã¯ãªããäž»é£ã®éã2ãã3岿žãããçã飲ã¿ç©ãæ°Žããè¶ã«çœ®ãæããã ãã§ããèèãžã®è² æ
ã¯å€ããã
ç¹ã«èŠèœãšãããã®ããæž æ¶Œé£²ææ°ŽããšããžãŒããªã³ã¯ã«å ¥ã£ãŠããæç³ãããŠç³æ¶²ç³ã ãæç³ã¯èèã«å ¥ãããããèèªåæã«åãããããæ¯æ¥é£²ãã§ãã人ã¯ãããããå€ããã ãã§ããã
å èèèªãæžããã®ã¯ãæé žçŽ ãçãã¬ã
èªåã¯çãã¬åŽã®äººéã ãããã§ããå èèèªãæžãããšããäžç¹ã«çµããªããéåã®äž»åœ¹ã¯æé žçŽ ã ãšæã£ãŠããã2026幎ã«ãåç³å°¿ç ãš2åç³å°¿ç ã®äººã察象ã«ãã33詊éšã»1,740åã®ãããã¯ãŒã¯ã¡ã¿è§£æãåºãâ¹âŸã
æé žçŽ éåïŒãããïŒ
é«åŒ·åºŠã€ã³ã¿ãŒãã«ïŒHIIT)
è€åãã¬ãŒãã³ã°ïŒæé žçŽ ãšçãã¬ãåãããŠè¡ã圢åŒïŒ
ã¯ãããã察ç
§ãšæ¯ã¹ãŠå
èèèªãææã«æžããããçãã¬åç¬ã ãã§ã¯ãå€ãããªãã£ããéåã®çš®é¡ãé äœã¥ãããçµæã§ããäžããè€åãã¬ãŒãã³ã°ãé«åŒ·åºŠã€ã³ã¿ãŒãã«ãæé
žçŽ ãçãã¬åç¬ã®é ã ã£ãã
çãã¬åç¬ã«ãããã¡ããæå³ã¯ãããå¥åº·ãªæäººã§ã¯ãçãã¬ã ãã§ãå
èèèªãæžã£ããšå ±åãããŠããâµâŸâ¶âŸããã ã广ã¯åçãšããããå°ããã ã34ç ç©¶ã»2,285åã®ã¡ã¿åæã§ã¯ãé£äºå¶éã«çãã¬ãè¶³ããŠããå
èèèªã®æžãã§ã¯é£äºå¶éã ããšã®å·®ã確èªã§ããªãã£ãâ¶âŸã

ãã¯ããå èèèªãæžããå Žé¢ã®äž»åœ¹ã¯ãé£äºãšæé žçŽ ã®ã»ãã ã
ãããçãã¬ã¯èŠããªãã®ããšãããšããã§ã¯ãªããŠã圹å²ãéããçç±ã¯ã·ã³ãã«ã§ãçèã¯è¡ç³ã®å€§ããªåãç¿ã ããã ãçèéãå¢ããã°ãåºç€ä»£è¬ã ãã§ãªããè¡ç³ãåãæ¢ããåãäžãããã€ã³ã¹ãªã³ãå¹ãããããªããTOFIã®æ ¹ã£ãã«ããã®ã¯çèéã®äœäžã§ãçèéãå¢ããã®ã¯æé
žçŽ ã§ã¯ãªãçãã¬ãæžããã®ã¯é£äºãšæé
žçŽ ãããŸãã«ããäœãäœãã®ã¯çãã¬ãããåããŠèããŠããã
ããããšã¯åçŽã ãæé
žçŽ ã¯ãæ¯ãå°ãäžããçšåºŠã§okãé±150åãç®æããããéå€ã®æ©æ©ãã§çšŒãã§ãããã
çãã¬ã¯ãžã ã«è¡ãããªãå
šèº«ãæºéãªãé±2åçšåºŠè¡ãããããžã ã«è¡ããªããªããèªéã¹ã¯ã¯ãããšè
ç«ãŠäŒãããã§ãããã
WHOã®éåæéããæé žçŽ é±150åãšçãã¬é±2æ¥ä»¥äžãã»ããã§ããããŠãããå®ç§ãªã¡ãã¥ãŒããããŒãã«ããªãããšã®ã»ãã倧äºã ã
æéããªã人ãçãã¬ãšæé
žçŽ ã«ã©ãåãçµãã°ããã®ãã¯ãæé
žçŽ ãæé«ã ãã§ãå
šéšã¯ã§ããªã人ãžïœæéããªã人ã®éåé
åã§æžããã
çãã¬ã¯é±2æéãããã§æ»äº¡ãšã®é¢é£ãé æã¡ãå¿èºæ©èœã¯æž¬ãããç¯å²ã§ã¯é æã¡ãèŠã€ãããªããé±2æ¥ããåããªã人ã®çµã¿æ¹ãŸã§ã
äœéãå€ãã£ãŠããªã人ã»ã©ã身äœã®äžèº«ãèŠã
ã倪ã£ãŠãªããã倧äžå€«ãã¯ãäžçªå±ãªãæã蟌ã¿ã ã
äœéèšã®æ°åã¯æ£åžžã§ãã身äœã®äžã§ã¯èèªãããŸããè¡ç³ç°åžžã»åè硬åã»èèªèã®ãªã¹ã¯ãé«ãŸã£ãŠãããããããªãã
ãããåä»ã ãèŠãç®ã«ããäœéã«ããèªèŠçç¶ã«ãåºãªããã ãããããæ°åã§ç¢ºãããããšãå¿ èŠã«ãªããèªåã¯ããŒãœãã«ãã¯ã¿ãŒãšããŠãçµå¶è ã«ããäŒããŠããã
ãäŒç€Ÿã®æ±ºç®æžã¯æ¯å¹ŽèŠãã§ãããã èªåã®èº«äœã®æ±ºç®æžãã幎ã«äžåºŠã¯éããŠã»ãã ã
äœéãå€ãã£ãŠããªããã倧äžå€«ã
ãã®æèŠèªäœã¯ãééãã§ã¯ãªãããã ã確ãããå Žæãéãã
çãã¯äœéèšã«ã¯ãªããå¥èšºç¥šã®äžèº«ã«ããã
ãŸãšã
TOFIã¯ãBMIæ£åžžã§ãå èèèªãèèªèãèŠãç®ä»¥äžã«é ããŠããç¶æ
BMIãæ£åžžã§ãè¡æ¶²æ€æ»ãè¡å§ã®æ°åãæªã人ã¯ãå¿è¡ç®¡çŸæ£ã®ãªã¹ã¯ãé«ã矀ã«å ¥ãããšããã
æ¥æ¬ã®èèªèã®äººã®çŽ2å²ãããåãç©ããŠããŠãèèªèã¯èµ·ãã
å¥èšºç¥šã§ã¯ãäžæ§èèªã»HDLã»HbA1cã»ALTã»Î³-GTPã»è¡å§ã»è ¹å²ã远ã
æ°ã«ãªã人ã¯è ¹éšãšã³ãŒãšæ¡è¡ãå¿ èŠãªãè ¹éšCTãè¿œå æ€æ»ãèãã
å èèèªãæžãã䞻圹ã¯é£äºãšæé žçŽ ãçãã¬ã¯è¡ç³ã®åãç¿ãå¢ãããŠãããŸãã«ããäœãäœã
ãããŸã§èªãã§ãã ãã£ãŠãããããšãããããŸããã
圹ã«ç«ã£ãããã¹ããããããããšããããå±ã¿ã«ãªããŸãã èªåã®äœã§ã詊ããå¥åº·ã®è©±ããããããªããŒãã§ãæ°æ¥ã«1æ¬ãããåºããŠããŸãã
ãã²ãã©ããŒããŠããããšå¬ããã§ãã
ãã£ãšæ·±ãç¥ãããæ¹ãžïŒé¢é£èšäºïŒ
ãã®å
ã¯ãçãã¬ãšäŒé£å¯Ÿçã®2æ¬ã«åããŠèªãã®ãããããã§ãã
⌠çãã¬ãã©ãããå§ããã
远ã蟌ã¿ãè¥å€§ã¬ã³ãžããèŠããªãã£ãïœç±³åœææ°çãã¬ã¬ã€ãã©ã€ã³è§£èª¬ïŒã¡ã³ããŒéå®ïŒ 远ã蟌ã¿ã»ééã»åæ°ã»ã»ããæ°ãã©ãèãããããç±³åœã®ææ°ã¬ã€ãã©ã€ã³ããå®è·µã«èœãšããŠããŸããé±2å30åã®å
ã«é²ã¿ãã人åãã§ãã
⌠æ¥åŸ
ãæžãããªã人ã®ãçŸå®çãªå€ãæ¹
æ¥åŸ
ãæžãããçµå¶è
ã®æ°å€ãäžãããåŒãç®ã®é£ã¹æ¹ïŒã¡ã³ããŒéå®ïŒ
åžã®30ååã®ãšãŒã°ã«ããç¿æã®ãµã猶ãç· ãã®ã«ããã倿¥ã§å®éã«ææ¡ããŠããæ¹æ³ããäžæ§èèªãšALTãã©ãåãããã®å
·äœäŸã€ãã§ãŸãšããŠããŸãã
ã¡ã³ããŒã·ãããDr.ãããã©ããã®ãç¥ãã
ã¡ã³ããŒã·ãããDr.ãããã©ãããéå¶ããŠããŸããXã»ç¡ænoteã§ã¯åºããªããããäžæ®µèžã¿èŸŒãã è©±ãæžããŠããŸãã
çµå¶è ã®äž»æ²»å»ãšããŠã倿¥ã§å®éã«è©±ããŠããå 容
è«æãèªã¿ãªããèªåã®äœã§è©Šãããå¹ããã»å¹ããªãã£ãèšé²
æ€æ»æ°å€ã®èªã¿æ¹ããµããªã»è¬ã®éžã³æ¹
ã¡ã³ããŒéå®ã®æ²ç€ºæ¿Q&A
æé¡1000åã§å šèšäºèªã¿æŸé¡ã§ããåããªãã£ããããè§£çŽã§ããŸããæ°ã«ãªã£ãæ¹ã¯ãèŠããŠã¿ãŠãã ããã
â»æ¬èšäºã¯äžè¬çãªå¥åº·ã»å»åŠæ
å ±ã®æäŸãç®çãšãããã®ã§ãããç¹å®ã®å人ã«å¯Ÿãã蚺æã»æ²»çã»å»åŠçå©èšãè¡ããã®ã§ã¯ãããŸãããå¥åº·äžã®æžå¿µãããå Žåã¯ãå¿
ãå»çæ©é¢ãå蚺ããŠãã ãããèšäºã®æ
å ±ã«åºã¥ãè¡åã®çµæã«ã€ããŠã¯ãçè
ã¯è²¬ä»»ãè² ããããŸãã
åèæç®
1) Thomas EL, Parkinson JR, Frost GS, Goldstone AP, Doré CJ, McCarthy JP, Collins AL, Fitzpatrick JA, Durighel G, Taylor-Robinson SD, Bell JD. The missing risk: MRI and MRS phenotyping of abdominal adiposity and ectopic fat. Obesity (Silver Spring). 2012;20(1):76-87. doi:10.1038/oby.2011.142. PMID:21660078.
2) Kramer CK, Zinman B, Retnakaran R. Are metabolically healthy overweight and obesity benign conditions?: A systematic review and meta-analysis. Ann Intern Med. 2013;159(11):758-769. doi:10.7326/0003-4819-159-11-201312030-00008. PMID:24297192.
Schulze MB. Metabolic health in normal-weight and obese individuals. Diabetologia. 2019;62:558-566. doi:10.1007/s00125-018-4787-8.
3) Ye Q, Zou B, Yeo YH, et al. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease. Lancet Gastroenterology & Hepatology. 2020;5(8):739-752.
4) Ito T, Ishigami M, Zou B, et al. The epidemiology of NAFLD and lean NAFLD in Japan: a meta-analysis. Hepatology International. 2021;15:366-379.
5) Wewege MA, Desai I, Honey C, et al. The Effect of Resistance Training in Healthy Adults on Body Fat Percentage, Fat Mass and Visceral Fat. Sports Medicine. 2022;52(2):287-300.
6) Khalafi M, Malandish A, Rosenkranz SK, et al. Effect of resistance training with and without caloric restriction on visceral fat. Obesity Reviews. 2021;22(9):e13275.
7) Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78(6):1966-1986. doi:10.1097/HEP.0000000000000520. PMID:37363821.
8) Hiuge-Shimizu A, Kishida K, Funahashi T, et al. Absolute value of visceral fat area measured on computed tomography scans and obesity-related cardiovascular risk factors in large-scale Japanese general population (the VACATION-J study). Ann Med. 2012;44(1):82-92. doi:10.3109/07853890.2010.526138. PMID:20964583.
9) Khalafi M, Fatolahi S, Symonds ME, et al. Comparative Efficacy of Exercise Type on Visceral Adipose Tissue in Patients With Prediabetes and Type 2 Diabetes Mellitus: A Systematic Review With Pairwise and Network Meta-Analyses. Obesity Reviews. 2026;27(3):e70031. doi:10.1111/obr.70031. PMID:41062106.